• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1(PAI-1)和白细胞介素-6(IL-6)基因多态性与吸烟在确定它们与冠状动脉疾病相关风险中的协同作用。

Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease.

作者信息

Sarecka Beata, Zak Iwona, Krauze Jolanta

机构信息

Department of Biochemistry and Medical Genetics, Medical University of Silesia, Medykow Str 18, 40-752 Katowice, Poland.

出版信息

Clin Biochem. 2008 May;41(7-8):467-73. doi: 10.1016/j.clinbiochem.2008.01.028. Epub 2008 Feb 15.

DOI:10.1016/j.clinbiochem.2008.01.028
PMID:18307986
Abstract

OBJECTIVES

To assess the relationship between IL-6 and PAI-1 polymorphisms and coronary artery disease (CAD) and to observe the interactions between these polymorphic variants and smoking in the CAD risk.

DESIGN AND METHOD

The study population consisted of 178 patients with angiographically documented CAD and 202 blood donors. The analyses of genetic polymorphisms were performed using the PCR-RFLP method.

RESULTS

The frequency of PAI-1 5G allele was higher in the entire CAD group than in control group (p=0.04, OR=1.35). Also the 5G allele carriers (4G5G+5G5G) were more frequent in patients than in controls (p=0.03, OR=1.93). The number of women carrying 5G allele was again significantly higher among patients (OR=10.95 p=0.0075). The IL-6 C allele frequency was higher only in the CAD male subgroup (p=0.035, OR=1.44). We found synergistic and cumulative effects between specific genotype patterns and smoking in determining the risk of CAD, especially between PAI-1(4G5G+5G5G)+IL-6(CC) and smoking (SIM=4.18 and p=0.0005, OR=9.20, respectively).

CONCLUSIONS

There are synergistic and cumulative effects of 5G allele of PAI-1 polymorphism and C allele of IL-6 polymorphism with smoking in determining their associated risk with CAD.

摘要

目的

评估白细胞介素-6(IL-6)和纤溶酶原激活物抑制剂-1(PAI-1)基因多态性与冠状动脉疾病(CAD)之间的关系,并观察这些多态性变体与吸烟在CAD风险中的相互作用。

设计与方法

研究人群包括178例经血管造影证实患有CAD的患者和202名献血者。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法进行基因多态性分析。

结果

整个CAD组中PAI-1 5G等位基因的频率高于对照组(p = 0.04,比值比[OR]=1.35)。患者中5G等位基因携带者(4G5G + 5G5G)也比对照组更常见(p = 0.03,OR = 1.93)。携带5G等位基因的女性患者数量再次显著高于对照组(OR = 10.95,p = 0.0075)。IL-6 C等位基因频率仅在CAD男性亚组中较高(p = 0.035,OR = 1.44)。我们发现特定基因型模式与吸烟之间在确定CAD风险方面存在协同和累积效应,特别是PAI-1(4G5G + 5G5G)+IL-6(CC)与吸烟之间(协同指数[SIM]=4.18,p = 0.0005,OR分别为9.20)。

结论

PAI-1基因多态性的5G等位基因和IL-6基因多态性的C等位基因与吸烟在确定它们与CAD相关风险方面存在协同和累积效应。

相似文献

1
Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease.纤溶酶原激活物抑制剂-1(PAI-1)和白细胞介素-6(IL-6)基因多态性与吸烟在确定它们与冠状动脉疾病相关风险中的协同作用。
Clin Biochem. 2008 May;41(7-8):467-73. doi: 10.1016/j.clinbiochem.2008.01.028. Epub 2008 Feb 15.
2
Cigarette smoking, carrier state of A or G allele of 46A>G and 79C>G polymorphisms of beta2-adrenergic receptor gene, and the risk of coronary artery disease.吸烟、β2肾上腺素能受体基因46A>G和79C>G多态性的A或G等位基因携带状态与冠状动脉疾病风险
Kardiol Pol. 2008 Apr;66(4):380-6; discussion 387.
3
Contemporaneous carrier-state of two or three "proatherosclerotic" variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals.APOE、ICAM1、PPARA和PAI-1基因的两到三种“动脉粥样硬化前期”变体的同期携带状态可区分CAD患者与健康个体。
Clin Chim Acta. 2005 Dec;362(1-2):110-8. doi: 10.1016/j.cccn.2005.06.011. Epub 2005 Jul 25.
4
Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease.对氧磷酶1基因Q192R多态性与某些传统危险因素在早发性冠状动脉疾病中的协同作用。
Arch Med Res. 2007 Jul;38(5):545-50. doi: 10.1016/j.arcmed.2007.03.004.
5
Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy.纤溶酶原激活物抑制剂-1基因多态性对原发性膜性肾病的影响。
Nephrol Dial Transplant. 2008 Oct;23(10):3166-73. doi: 10.1093/ndt/gfn258. Epub 2008 May 21.
6
[Association of PAI-1 gene polymorphism with prognosis of coronary artery disease].[纤溶酶原激活物抑制剂-1基因多态性与冠状动脉疾病预后的关系]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Apr;25(2):233-5.
7
Carrier-state of two or three polymorphic variants of MTHFR, IL-6 and ICAM1 genes increases the risk of coronary artery disease.亚甲基四氢叶酸还原酶(MTHFR)、白细胞介素-6(IL-6)和细胞间黏附分子-1(ICAM1)基因的两到三种多态性变体的携带状态会增加冠状动脉疾病的风险。
Kardiol Pol. 2008 Dec;66(12):1269-77.
8
[Relationship between polymorphisms of plasminogen activator inhibitor-1 promoter gene and pulmonary thromboembolism in Chinese Han population].[纤溶酶原激活物抑制剂-1启动子基因多态性与中国汉族人群肺血栓栓塞症的关系]
Zhonghua Yi Xue Za Zhi. 2006 May 23;86(19):1313-7.
9
Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients.纤溶酶原激活物抑制剂-1基因多态性(4G/5G)可预测非高脂血症心肌梗死后患者的复发情况。
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):548-54. doi: 10.1161/ATVBAHA.107.155556. Epub 2007 Dec 20.
10
Platelet polymorphisms: frequency distribution and association with coronary artery disease in an Indian population.血小板多态性:在印度人群中的频率分布及与冠状动脉疾病的关系。
Platelets. 2011;22(2):85-91. doi: 10.3109/09537104.2010.522275. Epub 2010 Oct 29.

引用本文的文献

1
Genetic Associations of Plasminogen Activator Inhibitor-1-Related miRNA Variants with Coronary Artery Disease.纤溶酶原激活物抑制剂-1 相关 miRNA 变异与冠状动脉疾病的遗传关联。
Int J Mol Sci. 2024 Oct 27;25(21):11528. doi: 10.3390/ijms252111528.
2
Plasminogen Activator Inhibitor-1 Polymorphisms and Risk of Coronary Artery Disease: Evidence From Meta-Analysis and Trial Sequential Analysis.纤溶酶原激活物抑制剂-1 多态性与冠心病风险:来自荟萃分析和试验序贯分析的证据。
Biochem Genet. 2022 Oct;60(5):1409-1445. doi: 10.1007/s10528-021-10143-x. Epub 2022 Jan 18.
3
Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis.
白细胞介素 6-174 G/C 多态性与冠心病及循环白细胞介素 6 水平的关系:系统评价和荟萃分析。
Inflamm Res. 2021 Dec;70(10-12):1075-1087. doi: 10.1007/s00011-021-01505-7. Epub 2021 Sep 30.
4
The IL-6 rs1800795 and rs1800796 polymorphisms are associated with coronary artery disease risk.白细胞介素 6(rs1800795 和 rs1800796)多态性与冠心病风险相关。
J Cell Mol Med. 2020 Jun;24(11):6191-6207. doi: 10.1111/jcmm.15246. Epub 2020 May 6.
5
Lack of Associations Between and Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and Meta-Analysis.与动脉缺血性脑卒中的相关性研究:系统评价与荟萃分析。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619869500. doi: 10.1177/1076029619869500.
6
Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases: a meta-analysis of 74 studies with 86,229 subjects.白细胞介素6(rs1800795)基因多态性与心血管疾病相关:一项对74项研究、86229名受试者的荟萃分析。
EXCLI J. 2019 Jun 7;18:331-355. doi: 10.17179/excli2019-1248. eCollection 2019.
7
Gene polymorphism associated with TNF-α (G308A) IL-6 (C174G) and susceptibility to coronary atherosclerotic heart disease: A meta-analysis.与肿瘤坏死因子-α(G308A)、白细胞介素-6(C174G)相关的基因多态性与冠状动脉粥样硬化性心脏病易感性的荟萃分析
Medicine (Baltimore). 2019 Jan;98(2):e13813. doi: 10.1097/MD.0000000000013813.
8
Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis.白细胞介素-6 基因多态性与冠心病的关联:一项更新的系统评价和累积荟萃分析。
Inflamm Res. 2015 Sep;64(9):707-20. doi: 10.1007/s00011-015-0850-9. Epub 2015 Jul 15.
9
PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.纤溶酶原激活物抑制剂-1 4G/5G多态性与冠状动脉疾病风险:一项荟萃分析。
Int J Clin Exp Med. 2015 Feb 15;8(2):2097-107. eCollection 2015.
10
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis.纤溶酶原激活物抑制剂-1 4G/5G多态性与冠状动脉疾病风险相关:一项荟萃分析。
Int J Clin Exp Med. 2014 Oct 15;7(10):3777-88. eCollection 2014.